




Lungenkrebs

Epidemiologie

Bösartige Neubildungen der Lunge im Zeitverlauf
altersstandardisierte Raten auf 100.000 Personen
(WHO-Weltbevölkerung, 2001)




Q: STATISTIK AUSTRIA, Österreichisches Krebsregister (Stand 02.10.2015) und Todesursachenstatistik.
Erstellt am 14.10.2015.

Ursachen


80% durch Nikotin



Diagnose



Diagnose




Arten des Lungenkrebs

Nicht kleinzelliges Karzinom:


- Plattenepithelkarzinom
- Adenokarzinom
- Großzelliges Karzinom

Kleinzelliges Karzinom

Therapiemöglichkeiten




Personalisierte Medizin




Personalisierte Medizin


Your research dollars are at work finding new lung cancer mutations for Targeted Therapies.




Therapiemöglichkeiten



Zukunft-TKI



Zukunft- Immuntherapien




Immuntherapien

How Nivolumab works to treat cancer

Existing immunotherapies


← Attack cancer cells



Immune system
applies brake

Nivolumab

← Attacks cancer cells




Prevents immune system
from applying brake

Immuntherapien

	Nivolumab (n = 292)	Docetaxel (n = 290)
ORR, % (95% CI)	19 (15, 24)	12 (9, 17)
Odds ratio (95% CI) P-value^a	1.7 (1.1, 2.6) 0.0246	
Median time to response,^b mos (range)	2.1 (1.2–8.6)	2.6 (1.4–6.3)
Median DOR,^b mos (range)	17.2 (1.8–22.6+)	5.6 (1.2+–15.2+)
Ongoing response,^c %	52	14
Median PFS, mos (95% CI)	2.3 (2.2, 3.3)	4.2 (3.5, 4.9)
1-yr PFS rate, % (95% CI)	19 (14, 23)	8 (5, 12)
HR (95% CI) P-value	0.92 (0.77, 1.11) 0.3932	

Immuntherapien



Immuntherapie Studien an der Onkologie

- **Immuntherapie bei unbehandelten metastasierten NSCLC**
- **Immuntherapie Kombination bei vorbehandelten met. SCLC**
- **Molekulare Testung bei seltenen Formen inkl. Pleuramesotheliom**

Vielen Dank!